English 
PHC Holdings Corporation and its subsidiary Ascensia Diabetes Care, a global diabetes care company, announced that Ascensia has signed a memorandum of understanding to transfer the commercial operations for Eversense® Continuous Glucose Monitoring (CGM) systems to Eversense maker Senseonics Holdings, Inc.
Under its collaboration with Senseonics, Ascensia acquired exclusive global distribution rights for Eversense in 2020 and launched Eversense 365, the world’s first and only one-year CGM system, in the U.S. in October 2024. PHC Holdings Corporation and its subsidiaries are collectively known as PHC Group.
As Eversense continues to grow, its go-to-market approach has increasingly departed from Ascensia’s core blood glucose monitoring business. PHC Group, Ascensia, and Senseonics agree that unifying development, manufacturing, and distribution within Senseonics would enable Eversense to accelerate growth and realize its full potential faster than under the current structure. For PHC Group, this decision also aligns with its long-term business strategy (Value Creation Plan), which includes updating the company structure and portfolio to pursue operational efficiency.
こちらもお読みください： Hitachi and Partners build generative AI healthcare platformg
Following the signing of a definitive agreement, most of the Eversense commercial team at Ascensia including Brian Hansen, President of CGM, who led the successful U.S. Eversense 365 launch, would transition to Senseonics. PHC Group and Ascensia plan to transfer commercial operations for Eversense to Senseonics and utilize Transition Service Agreements as needed while Senseonics establishes its global infrastructure. The companies anticipate minimal disruption for business partners, patients and providers.
Koichiro Sato, Chief Operating Officer and Chief Strategy Officer of PHC Group and CEO of Ascensia, commented: “We are very proud to have worked with Senseonics on commercializing Eversense and we are committed to supporting Senseonics in establishing their own commercial operations and smoothly transitioning to them when we have a definitive agreement. PHC Group remains invested in Senseonics and will continue to explore additional growth opportunities in the diabetes space.”
Tim Goodnow, President and Chief Executive Officer of Senseonics, commented: “Eversense is truly differentiated from any other CGM system on the market, and we believe now is the time to bring manufacturing and commercialization together to allow Senseonics to grow and remain responsive to the future needs of people with diabetes. We truly appreciate the partnership and investment that PHC Group and Ascensia have made in Senseonics, and we look forward to welcoming the talented commercial team and continuing to build momentum for Eversense 365.”
ソース ビジネスワイヤー
日本語